The new 2014 non-GAAP EPS guidance represents 9-14% growth vs 2013.
Note: The non-GAAP 2014 EPS guidance includes contribution from the developed-markets branded-generics business sold to MYL (#msg-104271033 because this deal will not close until early 2015. (Starting in 3Q14, the business sold to MYL will be accounted for as a discontinued operation on the P&L statement.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.